Table 2.
Quantitative analysis and comparison of the pre- and posttreatment results of the 6 × 6 mm scan group.
| Metric | Pretreatment | Posttreatment | Change | % change | p valuea |
|---|---|---|---|---|---|
| LogMAR CDVA (mean ± SD) | 0.68 ± 0.34 | 0.47 ± 0.25 | −0.21 ± 0.27 | −30.9% | <0.001b |
| CMT (mean ± SD), μm | 422 ± 131 | 334 ± 98 | −88 ± 132 | −20.9% | <0.001b |
| PFT (mean ± SD), μm | 413 ± 76 | 364 ± 45 | −49 ± 72 | −11.9% | <0.001c |
| IOP (mean ± SD), mmHg | 17.6 ± 3.1 | 16.6 ± 3.7 | −0.31 ± 3.2 | −1.8% | 0.737c |
| Signal strength (mean ± SD) | 7.13 ± 1.57 | 7.15 ± 1.59 | 0.05 ± 1.04 | 0.7% | 0.884c |
| FAZ area (mean ± SD), mm2 | 0.37 ± 0.11 | 0.4 ± 0.16 | 0.03 ± 0.1 | 8.1% | 0.041c |
| FD-Full (mean ± SD) | 1.57 ± 0.04 | 1.54 ± 0.04 | −0.02 ± 0.05 | −1.3% | 0.003c |
| FD-SCP (mean ± SD) | 1.54 ± 0.04 | 1.52 ± 0.04 | −0.02 ± 0.05 | −1.3% | 0.021c |
| FD-DCP (mean ± SD) | 1.57 ± 0.04 | 1.54 ± 0.05 | −0.03 ± 0.05 | −1.9% | <0.001c |
| VD-Full (mean ± SD), % | 31.3 ± 5.58 | 28.8 ± 5.18 | −2.5 ± 5.72 | −8% | 0.01c |
| VD-SCP (mean ± SD), % | 27.8 ± 4.09 | 25.3 ± 4.78 | −2.53 ± 5.13 | −9.1% | 0.003c |
| VD-DCP (mean ± SD), % | 28.5 ± 5.28 | 25.5 ± 5.96 | −3.03 ± 6.24 | −10.6% | 0.004c |
| Skeleton VD-Full (mean ± SD), % | 9 ± 1.99 | 7.8 ± 1.76 | −1.2 ± 2.32 | −13.3% | 0.003c |
| Skeleton VD-SCP (mean ± SD), % | 7.77 ± 1.6 | 6.8 ± 1.62 | −0.97 ± 2.16 | −12.5% | 0.007c |
| Skeleton VD-DCP (mean ± SD), % | 8.9 ± 1.8 | 7.44 ± 2.03 | −1.45 ± 2.36 | −16.3% | <0.001c |
CDVA, corrected distance visual acuity; CMT, central macular thickness; DCP, deep capillary plexus; FAZ, foveal avascular zone; FD, fractal dimension; Full, full retinal thickness; IOP, intraocular pressure; LogMAR, logarithm of the minimum angle of resolution; PFT, parafoveal thickness; SCP, superficial capillary plexus; VD, vascular density. aStatistically significant if <0.05. bWilcoxon signed rank test. cPaired t-test.